Saluda Medical has announced that new data from multiple studies evaluating the company’s Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS) system will be featured in 11 separate presentations—including a pre-congress presentation, four plenary presentations, five oral poster presentations, and a Top 5 Best Abstract presentation—during the upcoming International Neuromodulation Society (INS) 14th World Congress, being held May 25–30, 2019 in Sydney, Australia.
Evoke measures the spinal cord’s response to stimulation (evoked compound action potential, or ECAP), adjusts on every pulse to optimise activation within the patient’s therapeutic window, and is designed to maintain long-term results through ECAP control.
Oral presentations by leading pain specialists will feature new three-month data from the Evoke US pivotal study, which marks the first double-blinded, randomised, controlled US pivotal study in SCS; additional results from the Avalon multicentre chronic study at 12 months, selected as a Top 5 Best Poster; and long-term results at 18-months from the Avalon study, the first chronic implant study of ECAP-controlled, closed-loop SCS conducted in Australia. Additional presentations will focus on medication titration during treatment with SCS, variability in energy delivery to the spinal cord and its implications, neurophysiological measurements, neuromonitoring, and potential causes for SCS failures.
John Parker, CEO of Saluda Medical, commented, “INS offers the opportunity to demonstrate new scientific evidence supporting our Evoke ECAP-Controlled, Closed-Loop SCS system for the treatment of chronic pain. With oral presentations from top-ranking leaders in the field of pain medicine and neuromodulation, we look forward to sharing the latest short- and long-term clinical results of our Evoke system at such a high-calibre meeting.”
